ENDRA Life Sciences Inc. (NASDAQ:NDRA) Sees Significant Drop in Short Interest

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 49,378 shares, a decline of 15.3% from the December 31st total of 58,311 shares. Based on an average daily trading volume, of 15,186 shares, the short-interest ratio is presently 3.3 days. Approximately 7.3% of the company’s shares are short sold. Approximately 7.3% of the company’s shares are short sold. Based on an average daily trading volume, of 15,186 shares, the short-interest ratio is presently 3.3 days.

Analysts Set New Price Targets

NDRA has been the subject of several research reports. Ascendiant Capital Markets lowered their target price on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating for the company in a report on Monday, December 8th. Wall Street Zen raised ENDRA Life Sciences to a “sell” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, ENDRA Life Sciences presently has a consensus rating of “Hold” and an average target price of $30.00.

ENDRA Life Sciences Price Performance

Shares of NDRA opened at $3.80 on Monday. The firm has a market capitalization of $2.85 million, a PE ratio of -0.14 and a beta of 0.01. ENDRA Life Sciences has a 1-year low of $2.90 and a 1-year high of $11.96. The company’s fifty day moving average price is $5.00 and its 200-day moving average price is $5.23.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its earnings results on Friday, November 14th. The company reported ($1.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.95) by $0.20. As a group, research analysts anticipate that ENDRA Life Sciences will post -47.46 EPS for the current fiscal year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.